Systematic review with meta-analysis: effects of probiotic fungi on irritable bowel syndrome
In: Beneficial MicrobesSearch for other papers by Q. Qing in
Current site
Google Scholar
Search for other papers by Y. Chen in
Current site
Google Scholar
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou North Avenue, Baiyun District, Guangzhou, Guangdong province, 510515, P.R. China
Search for other papers by D.K. Zheng in
Current site
Google Scholar
Search for other papers by M.L. Sun in
Current site
Google Scholar
Search for other papers by Y. Xie in
Current site
Google Scholar
Search for other papers by S.H. Zhang in
Current site
Google Scholar
Abstract
Treatment of irritable bowel syndrome (IBS) remains challenging for clinicians. Probiotic fungi may act as candidate options for IBS treatment, but systematic evaluation of their clinical value remains scarce. This study is aimed to assess the efficacy and the safety of probiotic fungi for IBS treatment by means of systematic review and meta-analysis. PubMed, Embase, Web of Science, and the Cochrane Library, were searched up to June 2022. Randomised controlled trials recruited subjects with prescriptions of probiotic fungi were eligible. Efficacy and safety of probiotic fungi were re-evaluated. Continuous data were pooled to obtain standardised difference in means (SMD) with a 95% confidence interval. The search strategy identified 120 articles of which 7 trial assessing 883 subjects were included in the analysis. Systematic data support that Saccharomyces helps to relieve abdominal pain/discomfort (SMD = −0.205,
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Abbas, Z., Yakoob, J., Jafri, W., Ahmad, Z., Azam, Z., Usman, M.W., Shamim, S. and Islam, M., 2014. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. European Journal of Gastroenterology and Hepatology 26: 630-639. https://doi.org/10.1097/MEG.0000000000000094.
-
Asmat, S., Shaukat, F., Asmat, R., Bakhat, H. and Asmat, T.M., 2018. Clinical efficacy comparison of Saccharomyces boulardii and lactic acid as probiotics in acute pediatric diarrhea. Journal of College of Physicians and Surgeons Pakistan 28: 214-217. https://doi.org/10.29271/jcpsp.2018.03.214.
-
Barboza, J.L., Talley, N.J. and Moshiree, B., 2014. Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs 74: 1849-1870. https://doi.org/10.1007/s40265-014-0292-7.
-
Bertazzoni, E., Donelli, G., Midtvedt, T., Nicoli, J. and Sanz, Y., 2013. Probiotics and clinical effects: is the number what counts? Journal of Chemotherapy 25: 193-212. https://doi.org/10.1179/1973947813Y.0000000078.
-
Cayzeele-Decherf, A., Pelerin, F., Leuillet, S., Douillard, B., Housez, B., Cazaubiel, M., Jacobson, G.K., Justen, P. and Desreumaux, P., 2017. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis. World Journal of Gastroenterology 23: 336-344. https://doi.org/10.3748/wjg.v23.i2.336.
-
Choi, C.H., Jo, S.Y., Park, H.J., Chang, S.K., Byeon, J.S. and Myung, S.J., 2011. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Journal of Clinical Gastroenterology 45: 679-683. https://doi.org/10.1097/MCG.0b013e318204593e.
-
Curro, D., Ianiro, G., Pecere, S., Bibbo, S. and Cammarota, G., 2017. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology 174: 1426-1449. https://doi.org/10.1111/bph.13632.
-
Dale, H.F., Rasmussen, S.H., Asiller, O.O. and Lied, G.A., 2019. Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients 11: 2048. https://doi.org/10.3390/nu11092048.
-
De Melo Pereira, G.V., de Oliveira Coelho, B., Magalhaes Junior, A.I., Thomaz-Soccol, V. and Soccol, C.R., 2018. How to select a probiotic? A review and update of methods and criteria. Biotechnology Advances 36: 2060-2076. https://doi.org/10.1016/j.biotechadv.2018.09.003.
-
Didari, T., Mozaffari, S., Nikfar, S. and Abdollahi, M., 2015. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World Journal of Gastroenterology 21: 3072-3084. https://doi.org/10.3748/wjg.v21.i10.3072.
-
Enck, P., Aziz, Q., Barbara, G., Farmer, A.D., Fukudo, S., Mayer, E.A., Niesler, B., Quigley, E.M.M., Rajilic-Stojanovic, M., Schemann, M., Schwille-Kiuntke, J., Simren, M., Zipfel, S. and Spiller, R.C., 2016. Irritable bowel syndrome. Nature Reviews Disease Primers 2: 14. https://doi.org/10.1038/nrdp.2016.14.
-
Ford, A.C., Harris, L.A., Lacy, B.E., Quigley, E.M.M. and Moayyedi, P., 2018. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 48: 1044-1060. https://doi.org/10.1111/apt.15001.
-
Ghorbani-Choboghlo, H., Nikaein, D., Khosravi, A.R., Rahmani, R. and Farahnejad, Z., 2019. Effect of microencapsulation on Saccharomyces cerevisiae var. boulardii viability in the gastrointestinal tract and level of some blood biochemical factors in Wistar rats. Iranian Journal of Microbiology 11: 160-165.
-
Hager, C.L., Isham, N., Schrom, K.P., Chandra, J., McCormick, T., Miyagi, M. and Ghannoum, M.A., 2019. Effects of a novel probiotic combination on pathogenic bacterial-fungal polymicrobial biofilms. mBio 10: e00338-00319. https://doi.org/10.1128/mBio.00338-19.
-
Holtmann, G.J., Ford, A.C. and Talley, N.J., 2016. Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology and Hepatology 1: 133-146. https://doi.org/10.1016/S2468-1253(16)30023-1.
-
Kabir, M.A., Ishaque, S.M., Ali, M.S., Mahmuduzzaman, M. and Hasan, M., 2011. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Medical Journal 20: 397-401.
-
Kelesidis, T. and Pothoulakis, C., 2012. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology 5: 111-125. https://doi.org/10.1177/1756283X11428502.
-
Li, Y.F., Zhu, C.R., Gong, X.L., Li, H.L., Xiong, L.K., Wang, K.J. and Liu, G.S., 2019. Beneficial effects of probiotic treatment on gut microbiota in very low birth weight infants. Gastroenterology Research and Practice 2019: 3682836. https://doi.org/10.1155/2019/3682836.
-
Lovell, R.M. and Ford, A.C., 2012. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical Gastroenterology and Hepatology 10: 712-721. https://doi.org/10.1016/j.cgh.2012.02.029.
-
Lu, Y., Guo, M.H., Bi, T.N. and Zhang, R.L., 2017. Therapeutic effects of flupentixol and melitracen combined with Saccharomyces boulardii in patients with diarrheapredominant irritable bowel syndrome. World Chinese Journal of Digestology 25: 1031-1036. https://doi.org/10.11569/wcjd.v25.i11.1031.
-
Maupas, J.L., Champemont, P. and Delforge, M., 1983. Traitement des colopathies fonctionnelles-Essai en double aveugle de l’ultra-levure (Treatment of irritable bowel syndrome with Saccharomyces boulardii – a double-blind, placebo controlled study) (French). Médicine et Chirurgie Digestives 12: 77-79.
-
McFarland, L.V., 2007. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Medicine and Infectious Disease 5: 97-105. https://doi.org/10.1016/j.tmaid.2005.10.003.
-
McFarland, L.V., 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology 16: 2202-2222. https://doi.org/10.3748/wjg.v16.i18.2202.
-
Moher, D., Liberati, A., Tetzlaff, J. and Altman, D.G., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6: e1000097. https://doi.org/10.1371/journal.pmed.1000097.
-
Nash, A.K., Auchtung, T.A., Wong, M.C., Smith, D.P., Gesell, J.R., Ross, M.C., Stewart, C.J., Metcalf, G.A., Muzny, D.M., Gibbs, R.A., Ajami, N.J. and Petrosino, J.F., 2017. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 5: 153. https://doi.org/10.1186/s40168-017-0373-4.
-
Pineton de Chambrun, G., Neut, C., Chau, A., Cazaubiel, M., Pelerin, F., Justen, P. and Desreumaux, P., 2015. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease 47: 119-124. https://doi.org/10.1016/j.dld.2014.11.007.
-
Preidis, G.A., Weizman, A.V., Kashyap, P.C. and Morgan, R.L., 2020. AGA technical review on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 159: 708-738, e704. https://doi.org/10.1053/j.gastro.2020.05.060.
-
Rousseaux, C., Bouguen, G., Dubuquoy, C., Dubuquoy, L., Vandekerckove, P. and Desreumaux, P., 2010. Saccharomyces cerevisiae CNCM I-3856 decreases intestinal pain through PPAR alpha activation in the gut. Gastroenterology 138: S51.
-
Serce, O., Benzer, D., Gursoy, T., Karatekin, G. and Ovali, F., 2013. Efficacy of Saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial. Early Human Development 89: 1033-1036. https://doi.org/10.1016/j.earlhumdev.2013.08.013.
-
Spiller, R., Pelerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M. and Justen, P., 2016. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol Journal 4: 353-362. https://doi.org/10.1177/2050640615602571.
-
Su, G.L., Ko, C.W., Bercik, P., Falck-Ytter, Y., Sultan, S., Weizman, A.V. and Morgan, R.L., 2020. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 159: 697-705. https://doi.org/10.1053/j.gastro.2020.05.059.
-
Szajewska, H. and Kolodziej, M., 2015. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology and Therapeutics 42: 793-801. https://doi.org/10.1111/apt.13344.
-
Van der Geest, A.M., Schukking, I., Brummer, R.J.M., van de Burgwal, L.H.M. and Larsen, O.F.A., 2022. Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Beneficial Microbes 13: 183-194. https://doi.org/10.3920/BM2021.0123.
-
Zhang, W., Zhu, B., Xu, J., Liu, Y., Qiu, E., Li, Z., He, Y., Zhou, H., Bai, Y. and Zhi, F., 2018. Bacteroides fragilis protects against antibiotic-associated diarrhea in rats by modulating intestinal defenses. Frontiers in Immunology 9: 1040. https://doi.org/10.3389/fimmu.2018.01040.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 298 | 298 | 29 |
| Full Text Views | 1 | 1 | 0 |
| PDF Views & Downloads | 0 | 0 | 0 |
Systematic review with meta-analysis: effects of probiotic fungi on irritable bowel syndrome
In: Beneficial MicrobesSearch for other papers by Q. Qing in
Current site
Google Scholar
PubMed
Search for other papers by Y. Chen in
Current site
Google Scholar
PubMed
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou North Avenue, Baiyun District, Guangzhou, Guangdong province, 510515, P.R. China
Search for other papers by D.K. Zheng in
Current site
Google Scholar
PubMed
Search for other papers by M.L. Sun in
Current site
Google Scholar
PubMed
Search for other papers by Y. Xie in
Current site
Google Scholar
PubMed
Search for other papers by S.H. Zhang in
Current site
Google Scholar
PubMed
Abstract
Treatment of irritable bowel syndrome (IBS) remains challenging for clinicians. Probiotic fungi may act as candidate options for IBS treatment, but systematic evaluation of their clinical value remains scarce. This study is aimed to assess the efficacy and the safety of probiotic fungi for IBS treatment by means of systematic review and meta-analysis. PubMed, Embase, Web of Science, and the Cochrane Library, were searched up to June 2022. Randomised controlled trials recruited subjects with prescriptions of probiotic fungi were eligible. Efficacy and safety of probiotic fungi were re-evaluated. Continuous data were pooled to obtain standardised difference in means (SMD) with a 95% confidence interval. The search strategy identified 120 articles of which 7 trial assessing 883 subjects were included in the analysis. Systematic data support that Saccharomyces helps to relieve abdominal pain/discomfort (SMD = −0.205,
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 298 | 298 | 29 |
| Full Text Views | 1 | 1 | 0 |
| PDF Views & Downloads | 0 | 0 | 0 |